Pharmacokinetics and Pharmacodynamics of Ceftizoxime in Patients with Dosages Adjusted for Renal Function

Study Objective. Our institution developed dosing guidelines for patients with renal impairment based on pharmacokinetic data and class‐specific pharmacodynamics. Ceftizoxime was chosen as a model agent to evaluate if the modified guidelines achieved similar minimal plasma concentration (Cpmin) and time above the minimum inhibitory concentration of the infecting organism (T>MIC) in patients with renal impairment versus those with normal renal function.

[1]  J. Treluyer,et al.  Drug Disposition in Cystic Fibrosis , 1998, Clinical pharmacokinetics.

[2]  T. Fabian,et al.  Pharmacokinetics of Aztreonam and Imipenem in Critically Ill Patients with Pneumonia , 1996, Pharmacotherapy.

[3]  D. Nicolau,et al.  Serum bactericidal activity of ceftizoxime and ceftriaxone against pathogens associated with community-acquired and nosocomial pneumonias. , 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[4]  J. Lettieri,et al.  Ciprofloxacin pharmacokinetics in burn patients , 1996, Antimicrobial agents and chemotherapy.

[5]  J. A. Kruse,et al.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections , 1996, Antimicrobial agents and chemotherapy.

[6]  G. Drusano,et al.  Dosing Adjustment of 10 Antimicrobials for Patients with Renal Impairment , 1995, The Annals of pharmacotherapy.

[7]  W. Craig.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. , 1995, Diagnostic microbiology and infectious disease.

[8]  A. Traynor,et al.  Aminoglycoside dosing weight correction factors for patients of various body sizes , 1995, Antimicrobial agents and chemotherapy.

[9]  R. Erkkola,et al.  Review of β-Lactam Antibiotics in Pregnancy , 1994 .

[10]  B. Zarowitz,et al.  Predictability of creatinine clearance estimates in critically ill patients , 1993, Critical care medicine.

[11]  J. Klein,et al.  Evaluation of New Anti-Infective Drugs for the Treatment of Respiratory Tract Infections , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  John Webster,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics, 8th ed , 1992 .

[13]  B. Danielson,et al.  Neurotoxicity Associated with Ceftazidime Therapy in Geriatric Patients with Renal Dysfunction , 1991, Pharmacotherapy.

[14]  O. Cars,et al.  Neurotoxicity of β-lactam antibiotics: predisposing factors and pathogenesis , 1991 .

[15]  J. Segal,et al.  Clinical Pharmacokinetics in Patients with Spinal Cord Injuries , 1989, Clinical pharmacokinetics.

[16]  A. Smith,et al.  In vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coli , 1989, Antimicrobial Agents and Chemotherapy.

[17]  J. Turnidge,et al.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.

[18]  L. Bush,et al.  Antibiotic selection and pharmacokinetics in the critically ill. , 1988, Critical care clinics.

[19]  G. Drusano,et al.  Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients , 1987, Antimicrobial Agents and Chemotherapy.

[20]  W. Craig,et al.  Kinetics of antimicrobial activity. , 1986, The Journal of pediatrics.

[21]  W. Jusko,et al.  Pharmacokinetics of aztreonam in patients with gram-negative infections , 1985, Antimicrobial Agents and Chemotherapy.

[22]  I. L. Smith,et al.  Role for dual individualization with cefmenoxime. , 1984, The American journal of medicine.

[23]  G. Hodges,et al.  Neurotoxicity of antibacterial agents , 1984, Annals of internal medicine.

[24]  R. I. Ogilvie,et al.  Drug information handbook. , 1983 .

[25]  R. Echols,et al.  Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function , 1983, Antimicrobial Agents and Chemotherapy.

[26]  H. Eagle,et al.  Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels. , 1950, The American journal of medicine.

[27]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[28]  K. E. Newhouse.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1986, The Yale Journal of Biology and Medicine.

[29]  R. Erkkola,et al.  Review of beta-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules. , 1994, Clinical pharmacokinetics.

[30]  W. Craig,et al.  Killing and regrowth of bacteria in vitro: a review. , 1990, Scandinavian journal of infectious diseases. Supplementum.

[31]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[32]  C. Wa,et al.  Killing and regrowth of bacteria in vitro: a review. , 1990 .